Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Wakefield Website

Lalage M. Wakefield, D.Phil.

Selected Publications

1)  Tang B, Böttinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, Wakefield LM.
Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency.
Nat Med. 4: 802-7, 1998.
[Journal]
2)  Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM.
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
J Clin Invest. 109: 1607-15, 2002.
[Journal]
3)  Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM.
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.
J Clin Invest. 112: 1116-24, 2003.
[Journal]
4)  Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, Shih J, Parks WT, Wakefield LM.
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.
Cancer Res. 67: 8643-52, 2007.
[Journal]
5)  Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM.
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.
Cancer Res. 68: 3835-43, 2008.
[Journal]
6)  Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M, Lee C, Varanasi L, Yang Y, Martinez LA, Luo J, Ambs S, Sharma S, Wakefield LM, Meltzer PS, Lal A.
A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis.
Oncogene. [Epub ahead of print], 2014.
[Journal]
7)  Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yang Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, Meltzer PS, Lal A.
A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster.
Mol. Cell. Biol. 34: 533-50, 2014.
[Journal]
8)  Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ.
Effective chemoimmunotherapy with anti-TGFß antibody and cyclophosphamide in a mouse model of breast cancer.
PLoS ONE. 9: e85398, 2014.
[Journal]
9)  Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS.
Pillars Article: production of transforming growth factor ß by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986. 163: 1037-1050.
J. Immunol. 192: 2939-52, 2014.
[Journal]
10)  Wakefield LM, Hill CS.
Beyond TGFß: roles of other TGFß superfamily members in cancer.
Nat. Rev. Cancer. 13: 328-41, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/17/2014.